US 12,128,212 B2
Adaptive zone model predictive control with a glucose and velocity dependent dynamic cost function for an artificial pancreas
Eyal Dassau, Cambridge, MA (US); Francis J. Doyle, III, Cambridge, MA (US); and Dawei Shi, Cambridge, MA (US)
Assigned to PRESIDENT AND FELLOWS OF HARVARD COLLEGE, Cambridge, MA (US)
Appl. No. 16/973,628
Filed by PRESIDENT AND FELLOWS OF HARVARD COLLEGE, Cambridge, MA (US)
PCT Filed Jun. 19, 2019, PCT No. PCT/US2019/037923
§ 371(c)(1), (2) Date Dec. 9, 2020,
PCT Pub. No. WO2019/246213, PCT Pub. Date Dec. 26, 2019.
Claims priority of provisional application 62/686,931, filed on Jun. 19, 2018.
Prior Publication US 2021/0162127 A1, Jun. 3, 2021
Int. Cl. A61M 5/172 (2006.01); G16H 10/60 (2018.01); G16H 20/17 (2018.01); G16H 40/40 (2018.01); G16H 40/67 (2018.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01); G16H 70/40 (2018.01); A61M 5/142 (2006.01)
CPC A61M 5/1723 (2013.01) [G16H 10/60 (2018.01); G16H 20/17 (2018.01); G16H 40/40 (2018.01); G16H 40/67 (2018.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01); G16H 70/40 (2018.01); A61M 2005/14208 (2013.01); A61M 2230/201 (2013.01)] 14 Claims
OG exemplary drawing
 
1. A system for the delivery of a glucose altering substance to a patient, the system comprising:
a glucose sensor configured to provide a sensor glucose measurement signal representative of a real time glucose concentration;
an insulin delivery device configured to deliver insulin to a patient in response to control signals; and
a controller programmed to receive the sensor glucose measurement signal from the glucose sensor, wherein the sensor glucose measurement signal received indicates a concentration of the real time glucose concentration in a bloodstream,
wherein the controller is further configured to enact an impeding glycemia protocol based on a zone model predictive control (MPC) algorithm in response to the real time glucose concentration, wherein the impeding glycemia protocol comprises determining a relationship between predicted glucose concentrations, a rate of change of the predicted glucose concentrations, and a set of control parameters that determine insulin doses above and below a patient-specific basal rate; wherein the set of control parameters comprise control input glucose velocity penalties; and wherein the control input glucose velocity penalties comprise separate sets of control input glucose velocity penalties for hyperlycemia and hypoglycemia;
wherein the controller is further configured to adapt the set of control parameters using the relationship determined,
determine a dosage of the glucose altering substance to administer, using the zone MPC algorithm with the control parameters, in real time, and
send a command to the insulin delivery device to administer the dosage of the glucose altering substance.